

Anne Marie Queenan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12077327/publications.pdf>

Version: 2024-02-01

29
papers

5,050
citations

304602

22
h-index

477173

29
g-index

30
all docs

30
docs citations

30
times ranked

4946
citing authors

#	ARTICLE	IF	CITATIONS
1	Carbapenemases: the Versatile $\hat{1}^2$ -Lactamases. <i>Clinical Microbiology Reviews</i> , 2007, 20, 440-458.	5.7	2,068
2	Novel Carbapenem-Hydrolyzing $\hat{1}^2$ -Lactamase, KPC-1, from a Carbapenem-Resistant Strain of <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1151-1161.	1.4	1,415
3	Carbapenem-Resistant Strain of <i>Klebsiella oxytoca</i> Harboring Carbapenem-Hydrolyzing $\hat{1}^2$ -Lactamase KPC-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3881-3889.	1.4	172
4	Molecular Correlation for the Treatment Outcomes in Bloodstream Infections Caused by <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> with Reduced Susceptibility to Ceftazidime. <i>Clinical Infectious Diseases</i> , 2002, 34, 135-146.	2.9	131
5	SME-Type Carbapenem-Hydrolyzing Class A $\hat{1}^2$ -Lactamases from Geographically Diverse <i>Serratia marcescens</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3035-3039.	1.4	123
6	Effects of Inoculum and $\hat{1}^2$ -Lactamase Activity in AmpC- and Extended-Spectrum $\hat{1}^2$ -Lactamase (ESBL)-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Clinical Isolates Tested by Using NCCLS ESBL Methodology. <i>Journal of Clinical Microbiology</i> , 2004, 42, 269-275.	1.8	123
7	Characterization of the Extended-Spectrum $\hat{1}^2$ -Lactamase Reference Strain, <i>Klebsiella pneumoniae</i> K6 (ATCC 700603), Which Produces the Novel Enzyme SHV-18. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2382-2388.	1.4	119
8	Pertactin-Negative Variants of <i>Bordetella pertussis</i> in the United States. <i>New England Journal of Medicine</i> , 2013, 368, 583-584.	13.9	95
9	Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-2009. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2298-2307.	1.3	91
10	Hydrolysis and Inhibition Profiles of $\hat{1}^2$ -Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 565-569.	1.4	89
11	Interactions of Ceftobiprole with $\hat{1}^2$ -Lactamases from Molecular Classes A to D. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3089-3095.	1.4	84
12	CTX-M-15 extended-spectrum $\hat{1}^2$ -lactamase from Nigerian <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 24-30.	1.3	72
13	Multidrug resistance among <i>Acinetobacter</i> spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 267-270.	0.8	67
14	Biochemical Characterization of $\hat{1}^2$ -Lactamases Bla1 and Bla2 from <i>Bacillus anthracis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2040-2042.	1.4	60
15	Cloning and Biochemical Characterization of FOX-5, an AmpC-Type Plasmid-Encoded $\hat{1}^2$ -Lactamase from a New York City <i>Klebsiella pneumoniae</i> Clinical Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3189-3194.	1.4	42
16	Novel Carbapenem-Hydrolyzing Oxacillinase OXA-62 from <i>Pandoraea pnomenusa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1330-1335.	1.4	42
17	SME-3, a Novel Member of the <i>Serratia marcescens</i> SME Family of Carbapenem-Hydrolyzing $\hat{1}^2$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3485-3487.	1.4	42
18	Effect of MexXY Overexpression on Ceftobiprole Susceptibility in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2785-2790.	1.4	33

#	ARTICLE	IF	CITATIONS
19	Detection systems for carbapenemase gene identification should include the SME serine carbapenemase. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 1-4.	1.1	33
20	First Detection of Metallo- β -Lactamase VIM-2 in <i>Pseudomonas aeruginosa</i> Isolates from Colombia. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 226-229.	1.4	28
21	VIM-15 and VIM-16, Two New VIM-2-Like Metallo- β -Lactamases in <i>Pseudomonas aeruginosa</i> Isolates from Bulgaria and Germany. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2977-2979.	1.4	25
22	Differential Selection of Single-Step AmpC or Efflux Mutants of <i>Pseudomonas aeruginosa</i> by Using Cefepime, Ceftazidime, or Ceftobiprole. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4092-4097.	1.4	25
23	New Variant of CTX-M-Type Extended-Spectrum β -Lactamases, CTX-M-71, with a Gly238Cys Substitution in a <i>Klebsiella pneumoniae</i> Isolate from Bulgaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4518-4521.	1.4	14
24	TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum β -Lactamase Produced by a Clinical Isolate of <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 2000-2003.	1.4	12
25	Clinical Manifestations and Molecular Characterization of Pertactin-Deficient and Pertactin-Producing <i>Bordetella pertussis</i> Children, Philadelphia 2007-2014. <i>Clinical Infectious Diseases</i> , 2017, 64, 60-66.	2.9	12
26	Increasing FIM2/3 antigen-content improves efficacy of <i>Bordetella pertussis</i> vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro. <i>Vaccine</i> , 2019, 37, 80-89.	1.7	12
27	Detection of 2 SME-1 carbapenemase-producing <i>Serratia marcescens</i> in Detroit. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 71, 325-326.	0.8	10
28	The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines. <i>Expert Review of Vaccines</i> , 2014, 13, 1265-1270.	2.0	6
29	Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible <i>Acinetobacter baumannii</i> isolates from nosocomial pneumonia patients. <i>Journal of Chemotherapy</i> , 2013, 25, 141-147.	0.7	5